Insulin Dosing Adjustments on Dialysis vs Non-Dialysis Days
Reduce total daily insulin dose by 25% on the day after hemodialysis compared to non-dialysis days, with the reduction primarily applied to basal insulin.
Evidence-Based Dosing Strategy
On Hemodialysis Days
- Basal insulin: Reduce by 25% from baseline dose 1
- Prandial (bolus) insulin: Generally maintain usual doses, though some reduction may be needed based on individual response 1
- Total daily dose: Expect approximately 15-25% reduction in overall insulin requirements 1, 2
On Non-Dialysis Days
- Continue standard basal-bolus regimen without reduction
- Use correction doses as needed for hyperglycemia
Physiologic Rationale
The reduction in insulin requirements post-dialysis stems from:
- Removal of uremic toxins that contribute to insulin resistance
- Decreased counter-regulatory hormone levels
- Altered glucose metabolism in the dialysis setting 1, 3
Critical timing consideration: The highest risk for hypoglycemia occurs within 24 hours after hemodialysis, with glucose nadirs typically occurring during this period 3. This necessitates the dose reduction specifically on the day following dialysis.
Clinical Trial Evidence
A randomized crossover study 2 directly compared adjusted versus non-adjusted insulin dosing in type 2 diabetes patients on hemodialysis:
- 25% dose reduction group: Lower hypoglycemia incidence (0.7% vs 3.3% per dialysis session, p=0.02)
- Hypoglycemic symptoms: Significantly reduced (0.7% vs 6.9%, p=0.001)
- Glycemic efficacy: Maintained despite dose reduction
A euglycemic clamp study 1 demonstrated:
- Basal insulin needs: 25% reduction post-dialysis (0.4 U/h pre-dialysis vs 0.3 U/h post-dialysis, p=0.01)
- Total insulin requirements: 15% overall reduction (23.6 IU/24h pre-dialysis vs 19.9 IU/24h post-dialysis)
- Bolus insulin: No significant change required
Practical Implementation Algorithm
Step 1: Calculate Baseline Doses
For insulin-naïve patients initiating therapy 4:
- Age ≥70 years or eGFR <60: 0.2-0.3 U/kg/day
- Blood glucose 140-200 mg/dL: 0.4 U/kg/day
- Blood glucose 201-400 mg/dL: 0.5 U/kg/day
- Split 50% basal, 50% prandial (divided before three meals)
Step 2: Adjust for Dialysis Schedule
Day of/after hemodialysis:
- Reduce basal insulin by 25%
- Monitor closely for hypoglycemia during and 24 hours post-dialysis
- Maintain prandial doses initially, adjust based on response
Non-dialysis days:
- Use full calculated doses
- Apply standard correction scales
Step 3: Monitor and Titrate
- Increase frequency of blood glucose monitoring during transition 5
- Use correction insulin scales appropriate for renal impairment (start with "insulin-sensitive" column) 4
- Adjust based on patterns over multiple dialysis cycles
Important Caveats
Glycemic Monitoring Challenges
- HbA1c unreliability: Shortened red blood cell lifespan in ESKD makes HbA1c less accurate 6, 7
- Alternative monitoring: Consider glycated albumin or continuous glucose monitoring (CGM) for better assessment 6, 3
- CGM benefits: Reveals asymptomatic hypoglycemia and intradialytic glucose fluctuations not captured by point-of-care testing 3, 8
Insulin Selection Considerations
For patients on basal insulin 5:
- Longer-acting analogs (glargine U-300, degludec): No timing change needed, but dose reduction still applies
- Other basal insulins (glargine U-100, detemir, NPH): Administer at consistent time daily, reduce dose on post-dialysis days
- Concentrated insulins: Use with caution; dosing errors more consequential in renal impairment 9
High-Risk Situations
Patients requiring extra vigilance 10, 4:
- Age ≥65-70 years
- Poor oral intake
- Concurrent illness
- History of hypoglycemia unawareness
- Multiple comorbidities
For these patients, consider starting with basal-plus regimen (basal insulin 0.1-0.25 U/kg/day plus correction doses) rather than full basal-bolus 10.
Systematic Review Findings
A 2022 systematic review 11 identified the 25% basal insulin reduction as the most common recommendation, though noted significant gaps in the literature regarding:
- Optimal percentage reduction (recommendations ranged 15-25%)
- Prandial insulin adjustments
- Peritoneal dialysis management
- Transitions between dialysis modalities
Recent evidence 12 confirms that 25% total daily dose reduction on hemodialysis days reduces hypoglycemia without increasing inflammatory markers (IL-6, TNF-α) associated with cardiovascular risk, though glycated albumin levels may increase slightly.
Emerging Technology
Advanced hybrid closed-loop (AHCL) systems show promise in this population 8, with automated basal rate adjustments during and between dialysis sessions, though data remain limited and cost may be prohibitive.